Skip to main content

Want a detailed portfolio tracker?

OverviewPerformanceMetricsFinancialsETFsIndustryCorrelations
Market CapEPSP/EP/SP/BSharesProfit MarginOperating MarginDebt to EquityRevenueEarningsEBITDAFree Cash FlowTotal DebtTotal AssetsROAROE

Inhibrx Biosciences (INBX) Profit Margin (2023 - 2025)

Inhibrx Biosciences (INBX) profit margin from Jun 30, 2023 to Jun 30, 2025. The current Inhibrx Biosciences (INBX) profit margin is -2203.85%. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual Profit Margin

Quarterly Profit Margin

Annual Profit Margin change of Inhibrx Biosciences (INBX)

YearProfit MarginChange
2025-10773.08%
-101.28%
2024843785.00%
-6392.73%
2023-13408.89%
N/A

Comparison Inhibrx Biosciences (INBX) profit margin with competitors

Inhibrx Biosciences (INBX) profit margin is -2203.85%.

TickerNameProfit MarginUpside
OMEROmeros Corporation871.00%-139.52%
PRTCPureTech Health plc American Depositary Shares793.00%-135.98%
ABEOAbeona Therapeutics Inc454.90%-120.64%
CHRSCoherus Biosciences Inc397.30%-118.03%
FBIOFortress Biotech Inc193.10%-108.76%
INVAInnoviva Inc119.90%-105.44%
ZVRAZevra Therapeutics Inc101.60%-104.61%
ABUSArbutus Biopharma Corp94.73%-104.30%
SAVACassava Sciences Inc.93.68%-104.25%
GLPGGalapagos NV86.83%-103.94%
CTNMContineum Therapeutics Inc - Class A83.13%-103.77%
BDTXBlack Diamond Therapeutics Inc80.77%-103.66%
NEUPNeuphoria Therapeutics Inc75.08%-103.41%
IPSCCentury Therapeutics Inc70.13%-103.18%
FULCFulcrum Therapeutics Inc69.26%-103.14%
CVACCureVac N.V.68.44%-103.11%
PRTAProthena Corporation plc64.05%-102.91%
QTTBQ32 Bio Inc61.90%-102.81%
AVIRAtea Pharmaceuticals Inc60.95%-102.77%
ASNDAscendis Pharma A/S57.30%-102.60%
PLXProtalix BioTherapeutics Inc54.27%-102.46%
HCWBHCW Biologics Inc53.42%-102.42%
AGENAgenus Inc52.20%-102.37%
CGENCompugen Ltd48.57%-102.20%
KRYSKrystal Biotech Inc48.07%-102.18%
RPRXRoyalty Pharma plc - Class A46.73%-102.12%
XOMAPXOMA Royalty Corp45.90%-102.08%
XOMAOXOMA Royalty Corp45.90%-102.08%
AUPHAurinia Pharmaceuticals Inc44.21%-102.01%
NXTCNextcure Inc43.49%-101.97%
CPRXCatalyst Pharmaceuticals Inc42.66%-101.94%
HALOHalozyme Therapeutics Inc39.83%-101.81%
ADMAAdma Biologics Inc39.59%-101.80%
XOMAXOMA Royalty Corp36.25%-101.64%
VRTXVertex Pharmaceuticals Inc34.53%-101.57%
EXELExelixis Inc34.46%-101.56%
SLNOSoleno Therapeutics Inc33.17%-101.51%
CRMDCorMedix Inc30.29%-101.37%
TNGXTango Therapeutics Inc29.52%-101.34%
ARGXArgen X SE28.20%-101.28%
CAICaris Life Sciences Inc - Class A27.98%-101.27%
JAZZJazz Pharmaceuticals plc27.42%-101.24%
SPROSpero Therapeutics Inc24.90%-101.13%
INCYIncyte Corp23.83%-101.08%
REGNRegeneron Pharmaceuticals Inc20.17%-100.92%
NAGENiagen Bioscience Inc20.07%-100.91%
ICCCImmucell Corp18.75%-100.85%
NERVMinerva Neurosciences Inc17.79%-100.81%
ALNYAlnylam Pharmaceuticals Inc16.99%-100.77%
ENVBEnveric Biosciences Inc16.64%-100.76%
TECHBio-Techne Corp16.39%-100.74%
HRMYHarmony Biosciences Holdings Inc15.08%-100.68%
ONCBeiGene Ltd15.02%-100.68%
RIGLRigel Pharmaceuticals14.71%-100.67%
BMRNBiomarin Pharmaceutical Inc13.77%-100.62%
VXRTVaxart Inc13.20%-100.60%
IMCRImmunocore Holdings plc12.16%-100.55%
VRNAVerona Pharma Plc11.56%-100.52%
TGTXTG Therapeutics Inc9.65%-100.44%
APLSApellis Pharmaceuticals Inc6.95%-100.32%
PTGXProtagonist Therapeutics Inc6.71%-100.30%
NUVBNuvation Bio Inc - Class A6.48%-100.29%
FBIOPFortress Biotech Inc6.40%-100.29%
GMABGenmab5.92%-100.27%
SRPTSarepta Therapeutics Inc2.98%-100.14%
BMEABiomea Fusion Inc2.37%-100.11%
ACADAcadia Pharmaceuticals Inc1.36%-100.06%
FENCFennec Pharmaceuticals Inc1.33%-100.06%
FOLDAmicus Therapeutics Inc0.91%-100.04%
HOTHHoth Therapeutics Inc0.17%-100.01%
BBLGBone Biologics Corp0.02%-100.00%